Literature DB >> 24145357

IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35.

Qianshan Tao1, Tianping Chen, Lili Tao, Huiping Wang, Ying Pan, Shudao Xiong, Zhimin Zhai.   

Abstract

Cytokine-induced killer (CIK) cells are usually generated from peripheral blood mononuclear cells with the stimulation of IL-2 in vitro. Unlike the conventional IL-2-stimulated CIK cells (IL-2-CIK cells), we investigated the characteristics and potential mechanism of IL-15-stimulated CIK cells (IL-15-CIK cells) in this study. Compared with IL-2-CIK cells, the percentage of CD3CD56 cells was significantly increased in IL-15-CIK cells, but the expression of regulatory T (Treg) cells and IL-35 was significantly decreased in IL-15-CIK cells. Meanwhile, the in vitro cytotoxicity against human myeloid leukemia cells K562 of IL-15-CIK cells was significantly augmented compared with IL-2-CIK cells. These data suggest that IL-15 may improve the cytotoxicity of CIK cells against leukemia cells by upregulating CD3CD56 cells and downregulating Treg cells and IL-35.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24145357     DOI: 10.1097/CJI.0000000000000001

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  15 in total

1.  Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.

Authors:  Giulia Mesiano; Roberta Zini; Giulia Montagner; Nicoletta Bianchi; Rossella Manfredini; Antonella Chillemi; Massimo Aglietta; Giovanni Grignani; Ilaria Lampronti; Erika Fiorino; Fabio Malavasi; Dario Sangiolo; Roberto Gambari; Davide Ferrari
Journal:  Mol Med       Date:  2017-08-09       Impact factor: 6.354

2.  Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).

Authors:  Leonard Christopher Schmeel; Frederic Carsten Schmeel; Christoph Coch; Ingo G H Schmidt-Wolf
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-08       Impact factor: 4.553

3.  Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.

Authors:  Rupa Narayan; Jonathan E Benjamin; Omid Shah; Lu Tian; Keri Tate; Randall Armstrong; Bryan J Xie; Robert Lowsky; Ginna Laport; Robert S Negrin; Everett H Meyer
Journal:  Biol Blood Marrow Transplant       Date:  2019-04-03       Impact factor: 5.742

Review 4.  Common gamma chain cytokines in combinatorial immune strategies against cancer.

Authors:  Stephanie R Pulliam; Roman V Uzhachenko; Samuel E Adunyah; Anil Shanker
Journal:  Immunol Lett       Date:  2015-11-17       Impact factor: 3.685

5.  Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.

Authors:  Yan Chen; Bei Chen; Ti Yang; Weiming Xiao; Li Qian; Yanbing Ding; Mingchun Ji; Xiaoqun Ge; Weijuan Gong
Journal:  Cell Mol Immunol       Date:  2015-09-14       Impact factor: 11.530

6.  Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.

Authors:  Baodan Yu; Junli Wang; Chen He; Wei Wang; Jianli Tang; Runhui Zheng; Chengzhi Zhou; Huanhuan Zhang; Zhiping Fu; Qiasheng Li; Jun Xu
Journal:  Exp Ther Med       Date:  2017-06-08       Impact factor: 2.447

Review 7.  A killer choice for cancer immunotherapy.

Authors:  Tobi L Schmidt; Robert S Negrin; Christopher H Contag
Journal:  Immunol Res       Date:  2014-05       Impact factor: 4.505

Review 8.  Cytokine-induced killer (CIK) cells: from basic research to clinical translation.

Authors:  Yelei Guo; Weidong Han
Journal:  Chin J Cancer       Date:  2015-03-05

9.  Targeting regulatory T cells in cytokine-induced killer cell cultures (Review).

Authors:  Qianshan Tao; Huiping Wang; Zhimin Zhai
Journal:  Biomed Rep       Date:  2014-02-07

Review 10.  Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies.

Authors:  Frederic Carsten Schmeel; Leonard Christopher Schmeel; Sanna-Marie Gast; Ingo G H Schmidt-Wolf
Journal:  Int J Mol Sci       Date:  2014-08-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.